X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vyvgart (efgartigimod alfa) is a USFDA approved neonatal Fc receptor blocker, which is being evaluated for the treatment of adult patients with primary sjogren’s disease.
Lead Product(s): Efgartigimod Alfa
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
VYVGART (efgartigimod alfa) is a USFDA approved neonatal Fc receptor blocker, which is approved for the treatment of adult patients with primary immune thrombocytopenia.
Lead Product(s): Efgartigimod Alfa
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Vyvgart Hytrulo is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, & recombinant human hyaluronidase PH20 (rHuPH20). It is being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy.
Lead Product(s): Efgartigimod,rHuPH20
Therapeutic Area: Neurology Product Name: Vyvgart Hytrulo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) is a human IgG1 antibody fragment marketed for intravenous use. It is approved for the treatment of Generalized myasthenia gravis (gMG).
Lead Product(s): Efgartigimod Alfa,Hyaluronidase-qvfc
Therapeutic Area: Immunology Product Name: Vyvdura
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injection is being evaluated in phase 3 clinical trials for the treatment of pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Immunology Product Name: Efgartigimod SC
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
VYVGART Hytrulo, a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20, Halozyme’s ENHANZE® drug delivery technolog, is being developed for in adults with primary immune thrombocytopenia (ITP).
Lead Product(s): Efgartigimod Alfa,Hyaluronidase
Therapeutic Area: Immunology Product Name: Vyvgart Hytrulo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
Vyvgart (efgartigimod alfa-fcab) is a human IgG1 antibody fragment formulated with recombinant human hyaluronidase PH20 (rHuPH20). It is approved for the treatment of for generalized myasthenia gravis.
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
LEO 138559 (temtokibart) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Temtokibart
Therapeutic Area: Dermatology Product Name: LEO 138559
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Leo Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) injection is formulated with ENHANZE for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
The net proceeds will be used to accelerate company's commercial investment to propel Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and Vyvgart (efgartigimod alfa fcab) as a leading therapy globally.
Lead Product(s): Efgartigimod Alfa,Hyaluronidase-qvfc
Therapeutic Area: Immunology Product Name: Vyvgart Hytrulo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $1,270.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
